AR008927A1 - Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla - Google Patents

Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla

Info

Publication number
AR008927A1
AR008927A1 ARP970105735A ARP970105735A AR008927A1 AR 008927 A1 AR008927 A1 AR 008927A1 AR P970105735 A ARP970105735 A AR P970105735A AR P970105735 A ARP970105735 A AR P970105735A AR 008927 A1 AR008927 A1 AR 008927A1
Authority
AR
Argentina
Prior art keywords
water
pharmaceutical composition
active substance
medicinally active
dissolution
Prior art date
Application number
ARP970105735A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR008927A1 publication Critical patent/AR008927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Una composicion farmacéutica que comprende: i) una sustancia medicinalmente activa insoluble en agua, tal como formula (I), en la cual cada sustituyentetiene l significado dado en la descripcion; ii) tensioactivo(s), tal como el aceite de castorp olioxietilenado hidrogenado; y iii) portador(es) solido(s),tales como los polímeros solubles en agua. Dicha composicion puede ser preparada mediante (1) el agregado de los portadores solidos a solventesorgánicos, la disolucion de unasustanc ia medicinalmente activa insoluble en agua y los tensioactivos, y el amasado de la mezcla, y (2) luego de removerel o los solventes orgánicos, el secado y pulverizacion del residuo resultante. La composicion farmacéutica tienepropieda des de disolucion,absorcion oral, etc., muy satisfactorias.
ARP970105735A 1996-12-06 1997-12-05 Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla AR008927A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32661896 1996-12-06

Publications (1)

Publication Number Publication Date
AR008927A1 true AR008927A1 (es) 2000-02-23

Family

ID=18189823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105735A AR008927A1 (es) 1996-12-06 1997-12-05 Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla

Country Status (17)

Country Link
US (1) US6346537B1 (es)
EP (1) EP0943327B1 (es)
JP (1) JP4284706B2 (es)
KR (1) KR20000057242A (es)
CN (1) CN1149979C (es)
AR (1) AR008927A1 (es)
AT (1) ATE367150T1 (es)
AU (1) AU726451B2 (es)
BR (1) BR9713866A (es)
CA (1) CA2274485C (es)
DE (1) DE69737936T2 (es)
ES (1) ES2286835T3 (es)
HU (1) HU228680B1 (es)
RU (1) RU2197226C2 (es)
TW (1) TW426516B (es)
WO (1) WO1998024418A1 (es)
ZA (1) ZA9710927B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1064942T1 (en) 1998-03-26 2004-12-31 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparation of a macrolide
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
HUP0200483A3 (en) * 1999-03-11 2004-07-28 Fujisawa Pharmaceutical Co Liposome preparations
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
BR0307344A (pt) 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
MXPA06000370A (es) * 2003-07-09 2006-03-28 Chong Kun Dang Pharm Corp Dispersion solida de tacrolimus.
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US7994214B2 (en) 2003-08-29 2011-08-09 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
ATE531368T1 (de) * 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
US7652364B2 (en) * 2005-12-21 2010-01-26 Teradata Us, Inc. Crossing conductive traces in a PCB
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
KR100868295B1 (ko) * 2007-02-15 2008-11-11 풍림무약주식회사 레플루노미드를 함유하는 고체분산체 및 이의 제조방법
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
KR101714090B1 (ko) * 2008-07-08 2017-03-08 벨로시스 파마슈티컬스 에이/에스 이식 환자의 개선된 치료를 위한 타크로리무스
WO2010032958A2 (ko) * 2008-09-17 2010-03-25 씨제이제일제당 (주) 아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법
HUE028847T2 (en) 2010-02-17 2017-01-30 Veloxis Pharmaceuticals As Stabilized tacrolimus preparation
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
WO2011116034A1 (en) * 2010-03-17 2011-09-22 Lutran Industries, Inc. Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN105663092A (zh) * 2016-03-03 2016-06-15 海南华益泰康药业有限公司 一种含有他克莫司固体分散体的缓释胶囊及其制备方法
CA3056766A1 (en) 2016-05-26 2017-11-30 Dermala Inc. Compositions and methods for treating acne vulgaris

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
IE66485B1 (en) 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5817333A (en) 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
DK0669127T3 (da) 1992-11-18 1999-12-06 Fujisawa Pharmaceutical Co Farmaceutisk præparat med forlænget virkning
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Also Published As

Publication number Publication date
ES2286835T3 (es) 2007-12-01
EP0943327A4 (en) 2003-06-25
ATE367150T1 (de) 2007-08-15
ZA9710927B (en) 1998-06-15
HU228680B1 (en) 2013-05-28
CA2274485A1 (en) 1998-06-11
US6346537B1 (en) 2002-02-12
WO1998024418A1 (fr) 1998-06-11
EP0943327B1 (en) 2007-07-18
TW426516B (en) 2001-03-21
DE69737936T2 (de) 2007-12-06
HUP0000587A1 (hu) 2000-09-28
EP0943327A1 (en) 1999-09-22
CN1245424A (zh) 2000-02-23
AU5136998A (en) 1998-06-29
HUP0000587A3 (en) 2001-12-28
CN1149979C (zh) 2004-05-19
DE69737936D1 (de) 2007-08-30
RU2197226C2 (ru) 2003-01-27
BR9713866A (pt) 2000-03-14
AU726451B2 (en) 2000-11-09
CA2274485C (en) 2008-02-05
JP4284706B2 (ja) 2009-06-24
KR20000057242A (ko) 2000-09-15

Similar Documents

Publication Publication Date Title
AR008927A1 (es) Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
ES2620442T3 (es) Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
AR021539A1 (es) Preparaciones topicas anhidras para la piel
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
RU2001122708A (ru) Способы лечения рака яичника, поли (фосфоэфирные) композиции и способные подвергаться биологической деструкции изделия для этого предназначенные
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
CO6190598A2 (es) Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
ES2054690T3 (es) Uso farmaceutico de extractos de gramineas.
DK1212039T3 (da) Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
SI1171124T2 (sl) Antihelmintski sestavki
ES2058228T3 (es) Compuestos activos sobre el sistema cardiovascular.
AR036096A1 (es) Formulacion farmaceutica de sabor enmascarado, un procedimiento para su preparacion y un procedimiento de enmascaramiento del sabor de productos farmaceuticos
ES2195939T3 (es) Composicion para prevencion y/o tratamiento de trastornos circulatorios que comprende derivados de l-carnitina y extractos de ginkgo biloba.
AR010019A1 (es) Uso de por lo menos un principio activo, capaz de ser obtenido por extraccion de ginkgo biloba para la preparacion de composiciones farmaceuticas,y metodo de tratamiento cosmetico de pieles hiperreactivas.
ES2059471T3 (es) Un procedimiento para preparar un derivado de rodamina.
ES2167743T3 (es) Uso de piridil- y pirimidil-piperazinas en la preparacion de un medicamento para el tratamiento de trastornos derivados del abuso de substancias.
AR025015A1 (es) Composiciones para el ablandamiento del agua y detergentes
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration